• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
April

How To Replace The Irreplaceable

Biotech Letter

Everyone who told you AbbVie (ABBV) was going to collapse after the Humira patent cliff was not lying to you. They were just reasoning correctly from bad assumptions, which is far more dangerous.

The bear thesis was airtight on paper: Humira generated $21 billion annually at its peak, biosimilars were coming, and no drug in the history of the pharmaceutical industry had ever been successfully replaced at that scale by the same company.

Every single one of those facts was true. The conclusion they led to was completely wrong.

AbbVie spent the better part of a decade building two successor drugs. Skyrizi, targeting the IL-23 pathway, and Rinvoq, a JAK1 inhibitor, were not backup plans. They were the plan.

In Q1 2026, Skyrizi posted $4.5 billion in sales, up 29.2% year over year. Rinvoq added another $2.1 billion, up 20.2%. Together, $6.6 billion in a single quarter. Humira at its absolute peak never did that. The replacement didn't just fill the hole; it dug a bigger foundation underneath it.

What the bears consistently underestimated is how AbbVie engineered the succession.

Most pharma companies replace a blockbuster by going after an adjacent indication with a similar mechanism. AbbVie went after entirely new disease categories.

Skyrizi is now rapidly becoming the market leader in ulcerative colitis and Crohn's disease, indications Humira never dominated.

Management has guided Skyrizi to $33 billion in annual sales by 2031, with patent protection running into the mid-2030s. No biosimilar filing is expected before 2030.

That’s not a turnaround story but a decade-long runway with the gates locked behind it.

The Q1 2026 earnings report, AbbVie's eighth consecutive beat on both revenue and earnings, also crystallized something that tends to get lost in the immunology excitement: neuroscience is quietly becoming a second engine.

The neuroscience segment hit $2.9 billion in Q1 alone, up 24.3% year over year, with Vraylar contributing $905 million and Vyalev on what management is calling a blockbuster trajectory.

Full-year neuroscience guidance sits at $12.6 billion.

Add Tavapadon, a Parkinson's drug awaiting FDA approval in Q3 2026 that management projects as a $5 billion-plus franchise, and you start to see a company that has structurally diversified while everyone was staring at the Humira cliff.

The debt does exist and deserves honest treatment. AbbVie carries roughly $52.3 billion in net debt, partly a legacy of its $10.1 billion ImmunoGen acquisition in late 2023 and the earlier $63 billion Allergan deal. The current ratio sits at 0.67, which is tight.

But free cash flow is projected to rise 54% in fiscal 2026 to $27.5 billion, and the net debt to EBITDA ratio is on track to compress from 2.4 times to 1.6 times within the year.

A company generating that kind of cash flow does not stay overleveraged for long. The math works itself out, and AbbVie's management has proven they understand that.

On valuation, the stock trades at roughly 15 times forward earnings against a pharma peer average closer to 18 to 20 times. Merck (MRK) and Johnson & Johnson (JNJ) both trade at 19 to 20 times with materially lower earnings growth rates.

AbbVie is guiding for EPS of $14.37 to $14.57 for full-year 2026, up approximately 43% from fiscal 2025, with consensus estimates for fiscal 2027 converging in the $16 to $17 range. Even a modest re-rating toward peer multiples implies a stock price well north of current levels.

The macro environment is cooperating, too; in a slow-growth, sticky-inflation world with GDP running at 1.6% annualized and core CPI still elevated, institutional money rotates toward exactly this profile: a large-cap defensive with a 3% dividend yield, accelerating earnings, and unit demand that is completely inelastic to economic cycles.

People with autoimmune disease do not stop their biologics because the Fed raised rates.

The dip, when it comes, is the entry. The conclusion the bears got so spectacularly wrong turned out to be the best advertisement AbbVie ever had.

 

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 April https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png April2026-07-07 12:00:442026-07-07 12:21:18How To Replace The Irreplaceable
April

July 2, 2026

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
July 2, 2026
Fiat Lux

 

Featured Trade:

(HOW TO SURVIVE YOUR OWN GREATEST HIT)

(MRK), (ABBV), (DSNKY), (AZN)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 April https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png April2026-07-02 12:02:542026-07-02 12:07:38July 2, 2026
April

How To Survive Your Own Greatest Hit

Biotech Letter

In August 2015, Jimmy Carter announced he had melanoma that had spread to his liver and four spots on his brain. He was 90 years old.

He told reporters he thought he had a few weeks left, that he was "surprisingly at ease," and that he'd had a wonderful life. The five-year survival rate for stage IV melanoma at the time was 16%. His doctors were careful not to use the word "cure."

By December, he announced at his Sunday school class in Plains, Georgia, that his scans were clear and he no longer needed treatment. He lived another nine years and died at 100, the melanoma never returning.

The drug at the center of that story, pembrolizumab, had received FDA approval just 11 months before Carter's diagnosis. Merck (MRK) sells it under the name Keytruda, and in 2025 it generated $29.5 billion in revenues, making it the single best-selling prescription drug on the planet.

The problem, which Wall Street has been loudly arguing about for two years, is that the core patent expires in 2028.

I've watched patent cliffs panic the market before. AbbVie's (ABBV) Humira lost U.S. exclusivity in 2023 after pulling in north of $21 billion annually. By 2025, those revenues had cratered to roughly $4.5 billion.

Investors who bailed missed the point entirely - that AbbVie had spent years quietly constructing Rinvoq and Skyrizi as replacements, and those two drugs combined generated nearly $26 billion last year. The market punished AbbVie early and rewarded it late.

Merck is running the same playbook, and the stock has finally started reflecting that.

It has climbed 55% over the past 12 months, which sounds spectacular until you remember it spent most of 2024 and early 2025 being sold off despite Keytruda growing 12% year-over-year in Q1 2026. The market was pricing a melting ice cube. It was wrong.

Here’s what Merck has actually been doing while the bears held their funeral.

It acquired Terns Pharma for $6.7 billion, bringing in TERN-701, a tyrosine kinase inhibitor for chronic myeloid leukemia targeting a $5 billion market.

It completed the $9.2 billion acquisition of Cidara and its antiviral influenza candidate CD-388.

It bought Verona Pharma for roughly $10 billion, adding Ohtuvayre for COPD to the portfolio.

Most importantly for a company whose identity is oncology, it struck a partnership with Daiichi Sankyo (DSNKY) on antibody drug conjugates; $5 billion upfront, potentially $22 billion total.

ADCs are the most sophisticated targeted cancer therapy currently in clinical use, essentially precision-guided biological munitions that attach cytotoxic payloads directly to tumor cells.

Daiichi Sankyo already proved the concept with AstraZeneca (AZN) on Enhertu. Merck buying into that pipeline was not a panic move.

The math is sobering but manageable. Keytruda revenues are projected at $32.4 billion in 2026. By 2030, between generic erosion and the subcutaneous formulation Keytruda QLEX, I estimate that figure drops to around $17.2 billion combined.

Total approved product revenues slip from roughly $55.6 billion today to below $41.5 billion by 2030. The gap needs filling.

By my calculation, Merck's pipeline can generate approximately $17.35 billion in new product revenues by 2030 across 21 drug candidates, including the oral PCSK9 inhibitor enlicumab for hypercholesterolemia, anti-TROP2 ADC MK-2870 in oncology, and a deep bench of infectious disease and ophthalmology assets.

Add those together and 2030 revenues land around $77 billion, supporting a valuation of roughly $350 billion at the sector's average price-to-sales multiple; about 15% above where the stock trades today, with peak revenues for the new products still years ahead.

There will be a rough year, probably 2029, when the Keytruda cliff hits hardest, and the new drugs haven't yet built market share. Expect volatility. Use it.

The current traded price around $120 and a $297 billion market cap reflects a company the market spent 18 months treating like a one-drug story with an expiration date. What it actually is, increasingly, is a diversified late-stage pipeline trading at a discount to its own rebuild.

Jimmy Carter's doctors said they weren't looking for a cure, just control. Merck's management would recognize the strategy immediately.

 

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 April https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png April2026-07-02 12:00:002026-07-02 12:07:31How To Survive Your Own Greatest Hit
April

June 30, 2026

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
June 30, 2026
Fiat Lux

 

Featured Trade:

(DEAD SECTOR WALKING)

(CNC), (CI), (CVS), (AMZN)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 April https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png April2026-06-30 12:02:262026-06-30 13:08:18June 30, 2026
April

Dead Sector Walking

Biotech Letter

I've been doing this long enough to recognize the smell of a sector that's been left for dead.

I smelled it in Japanese banks in 1998 while everyone else was crowding into dot-coms. I smelled it in energy in 2016 when oil hit $26, and the obituaries were already written.

Right now, I'm smelling it in managed care.

The entire sector spent two years getting absolutely savaged. Medical cost ratios spiked to levels nobody modeled. Medicare Advantage reimbursement rates came in like a bad joke.

Management teams spent earnings calls in full apology mode. The stocks got cut in half. Investors fled.

And now, predictably, the same businesses that got obliterated are quietly putting up numbers that suggest the worst is behind them.

Three names caught my attention recently: Centene Corporation (CNC), The Cigna Group (CI), and CVS Health Corporation (CVS).

All three screen among the cheapest large-cap healthcare stocks in the market. All three just reported Q1 numbers that pointed in the right direction. And all three are still priced like the bleeding never stops.

CNC is the most interesting turnaround in the group. The company spent two years deliberately shedding unprofitable members by raising premiums, letting the sicker, costlier ones walk, and keeping the healthier base intact. Sounds counterintuitive. It worked.

The Medicaid Health Benefits Ratio has been falling. Medicare membership expanded 9.8% year-over-year. Q1 adjusted EPS landed at $3.37, up 16.2% year-over-year, on $49.94 billion in revenue.

The 2027 Medicare Advantage payment hike just got finalized at 2.48% year-over-year against an original proposal of 0.09%.

The stock trades at a 3-year PEG of 0.35x against a sector median of 1.70x. FY2026 is probably a trough year, and a pullback toward book value in the low $40s would be a better entry. The long-term bull case runs north of $90.

Cigna is the one the market has completely misread. Wall Street treats it like a shrinking insurer. The actual business looks nothing like that.

Q1 pharmacy revenue hit $54.04 billion, up 11.1% year-over-year, powered by zero out-of-pocket biosimilar programs for drugs like Humira and Stelara that are pulling patients away from brand-name pricing.

Behavioral health customers grew 17.7% to 27.6 million. Adjusted EPS beat estimates for the 19th time in the last 20 quarters.

The company expects to generate over $100 billion in biosimilar savings for the U.S. system in the years ahead, earning a service fee on every complex drug transition it manages.

Shares trade at a forward PE of under 10 against a 10-year average of 13.1. Fair value sits around $377. The stock is at $282. That gap doesn't close overnight, but it closes.

CVS is the most complicated and the most beaten. Eleven years of correction will do that to a stock's reputation, but the retail pharmacy headwinds are real.

Amazon (AMZN) is coming. Government reimbursement rates are outside management's control. None of that is news.

What is news is that the medical benefit ratio dropped to 84.6% in Q1, nearly back to 2022 levels. Health Care Benefits operating income jumped 68% year-over-year.

Revenue crossed $100 billion for the quarter. Management raised full-year adjusted EPS guidance to $7.30 to $7.50.

Even a conservative DCF built on 4% annual growth spits out an intrinsic value of $96. The realistic case, assuming free cash flow margins normalize toward historical averages, gets you to $132. Analysts are modeling an 11.26% EPS CAGR through 2030.

The setup across all three is the same. Costs spiked cyclically, and the market priced them as permanent. They're now coming down, and the market hasn't caught up yet.

I've seen this movie enough times to know how it ends. The HBRs stabilize, the reimbursement rates improve, and by the time the consensus upgrades roll in, half the move is already gone.

Eleven years is a long time to be cheap. These stocks are running out of reasons to stay that way.

 

 

 

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 April https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png April2026-06-30 12:00:212026-06-30 13:08:46Dead Sector Walking
April

June 25, 2026

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
June 25, 2026
Fiat Lux

 

Featured Trade:

(THE RAT POISON DISCOUNT)

(BMY)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 April https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png April2026-06-25 12:02:442026-06-25 12:21:16June 25, 2026
April

The Rat Poison Discount

Biotech Letter

For 70 years, the most widely prescribed blood thinner in the world was rat poison. Literally.

Warfarin started life in 1948 as a rodenticide marketed by the Wisconsin Alumni Research Foundation.

The pivot to human medicine came when a U.S. Army recruit tried to kill himself with the stuff in 1951, survived, and inadvertently ran the first human safety trial.

President Eisenhower was put on it after his 1955 heart attack, which is how rat poison became a medicine cabinet staple for a hundred million patients a year.

The drug that replaced warfarin for most of those patients is Eliquis, the single largest revenue generator at Bristol Myers Squibb (BMY). The market is currently treating BMY as though Eliquis is about to go the way of the rats.

That's a sloppy read of the situation.

In Q1 2026, BMY's Growth Portfolio generated $6.2 billion in revenue against $5.3 billion from the Legacy book.

A year earlier, both sides were running neck and neck at roughly $5.6 billion each. The crossover that most people had penciled in for "someday" already happened, and the stock is priced as though it hasn't.

At 9x forward earnings, a 48% discount to the sector median of 17.6x, the market is making a specific claim: that the patent cliff swallows the company whole and nothing credible grows on the other side. That claim stopped being accurate six weeks ago.

The Eliquis concern is real and I'm not going to paper over it.

EU patents expire in November 2026, generics are already entering European markets, and the IRA's Medicare price negotiations knocked roughly $1.2 billion off Q1 operating cash flow alone.

The question worth asking is whether that erosion is already in the price.

Run the Street's own bearish consensus numbers through a discounted cash flow, use a punitive 7.5% discount rate on a 0.45-beta defensive pharma, give the company zero credit for its $2 billion cost savings program, and you land at $68.50 per share. BMY trades around $54.

The cliff is in the model. The stock is still cheap.

What makes this interesting rather than just statistically cheap is the pipeline. Four late-stage catalysts land before year-end, and two are closer to regulatory formalities than coin flips.

Iberdomide, a next-generation CELMoD for multiple myeloma, has FDA breakthrough therapy designation, Priority Review, and a PDUFA date of August 17.

It works in patients who've become resistant to Revlimid and Pomalyst, the very drugs collapsing inside the Legacy Portfolio. Peak sales estimates run from $1 billion to $5 billion.

Mezigdomide just posted its second positive Phase III readout and is heading toward regulatory submission. Together, they don't just fill the Revlimid hole; they build a better franchise on top of it.

The two genuine binaries are milvexian and Cobenfy. Milvexian is a Factor XIa inhibitor in Phase III for atrial fibrillation and secondary stroke prevention.

The mechanism targets pathological clotting while leaving normal hemostasis largely intact; exactly the profile needed to reach the 40% of AFib patients currently undertreated because existing anticoagulants bleed them too aggressively.

That's roughly 2.4 million Americans without a viable option today.

If milvexian works, BMY hands off from one anticoagulant franchise to the next-generation version. A positive readout doesn't just soften the Eliquis cliff but it reroutes the revenue stream.

Cobenfy is the other swing. Alzheimer's disease psychosis, the hallucinations and delusions affecting 40% to 60% of Alzheimer's patients, has zero FDA-approved treatments.

The only serious competitor, Acadia's pimavanserin, already failed approval, which effectively cleared the field.

Cobenfy sidesteps the dopamine blockade that makes legacy antipsychotics dangerous in elderly dementia patients. JPMorgan projects $5 billion in peak sales across all indications by 2030.

You don't need all four to work.

Two positive readouts before December would force a model rebuild across the Street, and a 9x multiple would start looking embarrassingly wrong in hindsight.

A 4.35% dividend yield; nearly triple the sector median, pays you to wait.

Seventy-five years ago, the drug that kept Eisenhower alive was rat poison sold under a different label.

The market is making the same category error with BMY today; looking at the label, not what's inside the bottle.

 

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 April https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png April2026-06-25 12:00:492026-06-25 12:21:04The Rat Poison Discount
April

June 23, 2026

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
June 23, 2026
Fiat Lux

 

Featured Trade:

(THE CASE FOR ATTEMPT NUMBER 217)

(NVO), (LLY)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 April https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png April2026-06-23 12:02:362026-06-23 12:32:45June 23, 2026
April

The Case For Attempt Number 217

Biotech Letter

The first time I attempted an inverted maneuver in a MIG-29, my body had an opinion about it that my brain was not consulted on. At 7G, blood migrates south, whether you like it or not. My Russian co-pilot found this amusing.

The second time, I knew what was coming and managed to stay conscious for all of it. By the third, something clicked; not comfort exactly, but a grudging negotiation between what the aircraft demanded and what I could physically deliver.

That’s the only way you learn a machine like that. Repeated attempts, each one slightly less catastrophic than the last.

The chemists at Novo Nordisk (NVO) ran the same drill. The molecule that briefly made NVO the most valuable company in Europe, worth more than the entire Danish economy at its June 2024 peak, was not a first attempt. Semaglutide was compound number 217.

The team in Copenhagen synthesized and discarded 216 versions before the right configuration held. The breakthrough came when someone attached a fatty acid to the molecule, letting it piggyback on a blood protein and survive long enough to reach its target.

The unexpected side effect was that the compound also suppressed appetite with a potency nobody had planned for. They were building a diabetes drug. They stumbled into the obesity treatment that every pharmaceutical company on earth is now scrambling to replicate.

Then the stock fell 65% from its peak. That’s where we are now.

NVO's US revenue dropped 11% in Q1 2026, which looks alarming until you understand why. The company slashed GLP-1 prices to kill off compounders; the grey-market biosimilar operations were eating its lunch while NVO couldn't manufacture fast enough to meet demand. It worked.

NVO won in court, struck distribution agreements with the survivors, and controls the channel again. The price cuts are a one-time reset. Comparable sales will be measured against this new lower baseline starting in 2027, and the growth math becomes dramatically easier from there.

The product nobody is discussing loudly enough is the Wegovy pill. An oral GLP-1 drug that actually works is, pharmacologically speaking, something that shouldn't exist; peptides get destroyed in the stomach before they reach the bloodstream.

NVO cracked it using a carrier molecule that neutralizes stomach acid just long enough for the drug to slip through. The result is 207,000 prescriptions per week since launch.

Eli Lilly's (LLY) oral competitor is pulling 7,335. Average weight loss on NVO's pill runs 16.6% versus 12.4% for LLY's version. Patients and doctors have done the math.

Globally, NVO commands 55% of the injectable GLP-1 market. The obesity treatment market sits at $7.5 billion today and is projected to hit $67 billion by 2034, excluding diabetes entirely.

NVO does not need to gain a single point of market share to generate double-digit growth throughout that run.

The pipeline still has teeth. Wegovy HD is producing 20.7% average weight loss, with more than 30% of patients shedding a quarter of their body weight. CagriSema, the drug that triggered the December 2024 selloff when trial data disappointed, is on track for approval by year-end.

The market punished NVO as though the story was finished. It was reacting to a single chapter.

The valuation is the setup. NVO trades at a forward P/E of 12, against a five-year average closer to 29. The dividend has grown for 29 consecutive years, currently yielding 4.2% with a 50% payout ratio.

For a company running 83% gross margins with a product that outsells its nearest oral rival forty to one, a P/E of 12 is the market overshooting on the downside with the same conviction it overshoots on the upside.

One billion people worldwide live with obesity; only 2% are receiving treatment. That gap does not close by itself.

The third time in the cockpit, I stopped fighting the G-force and let the aircraft do its job. The same principle applies here.

 

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 April https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png April2026-06-23 12:00:482026-06-23 12:32:37The Case For Attempt Number 217
April

June 18, 2026

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
June 18, 2026
Fiat Lux

 

Featured Trade:

(BETTER RATED THAN THE GOVERNMENT)

(JNJ), (KVUE), (ISRG), (MSFT)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 April https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png April2026-06-18 12:02:522026-06-18 12:22:26June 18, 2026
Page 6 of 142«‹45678›»

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2026. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
Scroll to top